Your browser doesn't support javascript.
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France.
Charmet, Tiffany; Schaeffer, Laura; Grant, Rebecca; Galmiche, Simon; Chény, Olivia; Von Platen, Cassandre; Maurizot, Alexandra; Rogoff, Alexandra; Omar, Faïza; David, Christophe; Septfons, Alexandra; Cauchemez, Simon; Gaymard, Alexandre; Lina, Bruno; Lefrancois, Louise H; Enouf, Vincent; van der Werf, Sylvie; Mailles, Alexandra; Levy-Bruhl, Daniel; Carrat, Fabrice; Fontanet, Arnaud.
  • Charmet T; Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.
  • Schaeffer L; Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.
  • Grant R; Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.
  • Galmiche S; Sorbonne University, Paris, France.
  • Chény O; Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.
  • Von Platen C; Institut Pasteur, Centre for Translational Research, Paris, France.
  • Maurizot A; Institut Pasteur, Centre for Translational Research, Paris, France.
  • Rogoff A; Caisse Nationale d'Assurance Maladie, Paris, France.
  • Omar F; Caisse Nationale d'Assurance Maladie, Paris, France.
  • David C; Institut IPSOS, Paris, France.
  • Septfons A; Institut IPSOS, Paris, France.
  • Cauchemez S; Santé Publique France, Saint-Maurice, France.
  • Gaymard A; Institut Pasteur, Mathematical Modelling of Infectious Diseases Unit; UMR2000; CNRS, Paris, France.
  • Lina B; CNR des Virus des Infections Respiratoires, Institut des Agents Infectieux, Hospices Civils de Lyon.
  • Lefrancois LH; Virpath, Centre International de Recherche En Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, UCBL, Lyon, France.
  • Enouf V; CNR des Virus des Infections Respiratoires, Institut des Agents Infectieux, Hospices Civils de Lyon.
  • van der Werf S; Virpath, Centre International de Recherche En Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, UCBL, Lyon, France.
  • Mailles A; Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur CNRS UMR 3569; Université de Paris, Paris, France.
  • Levy-Bruhl D; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
  • Carrat F; Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur CNRS UMR 3569; Université de Paris, Paris, France.
  • Fontanet A; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
Lancet Reg Health Eur ; 8: 100171, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1397543
ABSTRACT

BACKGROUND:

We aimed to assess the effectiveness of two doses of mRNA COVID-19 vaccines against COVID-19 with the original virus and other lineages circulating in France.

METHODS:

In this nationwide case-control study, cases were SARS-CoV-2 infected adults with onset of symptoms between 14 February and 3 May 2021. Controls were non-infected adults from a national representative panel matched to cases by age, sex, region, population density and calendar week. Participants completed an online questionnaire on recent activity-related exposures and vaccination history. Information about the infecting virus was based on a screening RT-PCR for either B.1.1.7 or B.1.351/P.1 variants.

FINDINGS:

Included in our analysis were 7 288 adults infected with the original SARS-CoV-2 virus, 31 313 with the B.1.1.7 lineage, 2 550 with B.1.351/P1 lineages, and 3 644 controls. In multivariable analysis, the vaccine effectiveness (95% confidence interval) seven days after the second dose of mRNA vaccine was estimated at 88% (81-92), 86% (81-90) and 77% (63-86) against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively. Recent (2 to 6 months) history of virologically confirmed SARS-CoV-2 infection was found to be 83% (76-88), 88% (85-91) and 83% (71-90) protective against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively; and more distant (> 6 months) infections were 76% (54-87), 84% (75-90), and 74% (41-89) protective against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively.

INTERPRETATION:

In real-life settings, two doses of mRNA vaccines proved to be effective against COVID-19 with the original virus, B.1.1.7 lineage and B.1.351/P.1 lineages.

FUNDING:

Institut Pasteur, Research & Action Emerging Infectious Diseases (REACTing), Fondation de France (Alliance "Tous unis contre le virus").
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Journal: Lancet Reg Health Eur Year: 2021 Document Type: Article Affiliation country: J.lanepe.2021.100171

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Journal: Lancet Reg Health Eur Year: 2021 Document Type: Article Affiliation country: J.lanepe.2021.100171